| Category | Shares Offered | Lots | Amount (₹) |
|---|---|---|---|
| QIB (Qualified Institutional) | 1272000 | — | ₹— |
| NII / HNI (Non-Institutional) | 390000 | 3 | ₹3,87,000 |
| Retail (Individual) | 900000 | 2 | ₹2,58,000 |
| Market Maker | 1,38,000 | — | ₹— |
| Fresh Issue | 25,62,000 shares (agg. up to ₹11 Cr) | — | ₹— |
| Investor Type | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min 1 Lot) | 2 | 6,000 | ₹2,58,000 |
| HNI — sHNI | 3 | 9,000 | ₹3,87,000 |
| Metric | QIB | NII | Retail | Total |
|---|---|---|---|---|
| Subscription | 76.99 | 1664.45 | 874.20 | 598.69 |
| Shares | 1272000 | 390000 | 900000 | 2562000 |
| Bids | 97929000 | 649134000 | 786780000 | 1533843000 |
Amount in ₹ Crore
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 28 | 23 | 19 |
| PAT | 2 | 1 | 0 |
| EBITDA | 5 | 4 | 2 |
| Net Worth | 10 | 7 | 5 |
| Total Assets | 26 | 22 | 19 |
| Reserves | 1 | 3 | 2 |
| Borrowings | 11 | 11 | 10 |
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.
All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.
The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Competitive Strengths: